Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 574

1.

Treated Osteoporosis Is Still Osteoporosis.

Lewiecki EM, Binkley N, Bilezikian JP.

J Bone Miner Res. 2019 Feb 19:e3671. doi: 10.1002/jbmr.3671. [Epub ahead of print] No abstract available.

PMID:
30779859
2.

Quality of Life in Hypoparathyroidism Improves with rhPTH(1-84) Throughout 8 Years of Therapy.

Tabacco G, Tay YD, Cusano NE, Williams J, Omeragic B, Majeed R, Almonte MG, Rubin MR, Bilezikian JP.

J Clin Endocrinol Metab. 2019 Feb 18. pii: jc.2018-02430. doi: 10.1210/jc.2018-02430. [Epub ahead of print]

PMID:
30776291
3.

A Preliminary Assessment of Abdominal Wall Tension in Patients Undergoing Retromuscular Hernia Repair.

Tenzel PL, Johnson RG, Bilezikian JA, Powers WF, Hope WW.

Surg Technol Int. 2019 Feb 1;34. pii: sti34/1106. [Epub ahead of print]

PMID:
30716161
4.

Vitamin D supplementation and musculoskeletal health.

Bouillon R, Lips P, Bilezikian JP.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):85-86. doi: 10.1016/S2213-8587(18)30348-6. No abstract available.

PMID:
30683216
5.

Management of normocalcemic primary hyperparathyroidism.

Cusano NE, Cipriani C, Bilezikian JP.

Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):837-845. doi: 10.1016/j.beem.2018.09.009. Epub 2018 Sep 28. Review.

PMID:
30665550
6.

Pharmacology of Bisphosphonates.

Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG.

Br J Clin Pharmacol. 2019 Jan 16. doi: 10.1111/bcp.13867. [Epub ahead of print] Review.

PMID:
30650219
7.

Primary hyperparathyroidism.

Silva BC, Cusano NE, Bilezikian JP.

Best Pract Res Clin Endocrinol Metab. 2018 Sep 28. pii: S1521-690X(18)30113-1. doi: 10.1016/j.beem.2018.09.013. [Epub ahead of print] Review.

PMID:
30477754
8.

Primary hyperparathyroidism.

Silva BC, Cusano NE, Bilezikian JP.

Best Pract Res Clin Endocrinol Metab. 2018 Oct;32(5):593-607. doi: 10.1016/j.beem.2018.09.004. Epub 2018 Sep 22. Review.

PMID:
30449543
9.

New Directions in Treatment of Hypoparathyroidism.

Tabacco G, Bilezikian JP.

Endocrinol Metab Clin North Am. 2018 Dec;47(4):901-915. doi: 10.1016/j.ecl.2018.07.013. Review.

PMID:
30390821
10.

Signs and Symptoms of Hypoparathyroidism.

Cusano NE, Bilezikian JP.

Endocrinol Metab Clin North Am. 2018 Dec;47(4):759-770. doi: 10.1016/j.ecl.2018.07.001. Review.

PMID:
30390811
11.

Controversies in Vitamin D: Summary Statement From an International Conference.

Giustina A, Adler RA, Binkley N, Bouillon R, Ebeling PR, Lazaretti-Castro M, Marcocci C, Rizzoli R, Sempos CT, Bilezikian JP.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):234-240. doi: 10.1210/jc.2018-01414.

PMID:
30383226
12.

Proceedings of the 2018 Santa Fe Bone Symposium: Advances in the Management of Osteoporosis.

Lewiecki EM, Bilezikian JP, Giangregorio L, Greenspan SL, Khosla S, Kostenuik P, Krohn K, McClung MR, Miller PD, Pacifici R.

J Clin Densitom. 2019 Jan - Mar;22(1):1-19. doi: 10.1016/j.jocd.2018.09.010. Epub 2018 Sep 22. Review.

PMID:
30366683
13.

Skeletal and extra-skeletal actions of vitamin D: Current evidence and outstanding questions.

Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, Lips P, Munns CF, Lazaretti-Castro M, Giustina A, Bilezikian J.

Endocr Rev. 2018 Oct 12. doi: 10.1210/er.2018-00126. [Epub ahead of print]

PMID:
30321335
14.

Osteoanabolic and Dual Action Drugs.

Tabacco G, Bilezikian JP.

Br J Clin Pharmacol. 2018 Sep 15. doi: 10.1111/bcp.13766. [Epub ahead of print] Review.

PMID:
30218587
15.

Constituent analysis of iodine intake in Armenia.

Hutchings N, Aghajanova E, Baghdasaryan S, Qefoyan M, Sullivan C, He X, van der Haar F, Braverman L, Bilezikian JP.

Public Health Nutr. 2018 Nov;21(16):2982-2988. doi: 10.1017/S1368980018002197. Epub 2018 Sep 7.

PMID:
30189914
16.

Neonatal thyrotropin (TSH) screening as a tool for monitoring iodine nutrition in Armenia.

Hutchings N, Tovmasyan I, Hovsepyan M, Qefoyan M, Baghdasaryan S, Bilezikian JP.

Eur J Clin Nutr. 2018 Aug 31. doi: 10.1038/s41430-018-0298-4. [Epub ahead of print]

PMID:
30171226
17.

MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of Vitamin D.

Ebeling PR, Adler RA, Jones G, Liberman UA, Mazziotti G, Minisola S, Munns CF, Napoli N, Pittas AG, Giustina A, Bilezikian JP, Rizzoli R.

Eur J Endocrinol. 2018 Oct 12;179(5):R239-R259. doi: 10.1530/EJE-18-0151. Review.

PMID:
30131372
18.

Re: A History of Pivotal Advances in Clinical Research Into Bone and Mineral Diseases.

Miller PD, Bilezikian JP, Lewiecki EM, Watts NB, Carey JJ.

J Bone Miner Res. 2018 Oct;33(10):1900-1901. doi: 10.1002/jbmr.3566. Epub 2018 Aug 29. No abstract available.

PMID:
30102788
19.

Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis.

Cipriani C, Pepe J, Silva BC, Rubin MR, Cusano NE, McMahon DJ, Nieddu L, Angelozzi M, Biamonte F, Diacinti D, Hans D, Minisola S, Bilezikian JP.

J Bone Miner Res. 2018 Dec;33(12):2132-2139. doi: 10.1002/jbmr.3554. Epub 2018 Aug 8.

PMID:
30088838
20.

AHNS Series: Do you know your guidelines? Optimizing outcomes in reoperative parathyroid surgery: Definitive multidisciplinary joint consensus guidelines of the American Head and Neck Society and the British Association of Endocrine and Thyroid Surgeons.

Stack BC Jr, Tolley NS, Bartel TB, Bilezikian JP, Bodenner D, Camacho P, Cox JPDT, Dralle H, Jackson JE, Morris JC 3rd, Orloff LA, Palazzo F, Ridge JA, Scott-Coombes D, Steward DL, Terris DJ, Thompson G, Randolph GW.

Head Neck. 2018 Aug;40(8):1617-1629. doi: 10.1002/hed.25023. Epub 2018 Aug 2.

PMID:
30070413
21.

Primary Hyperparathyroidism.

Bilezikian JP.

J Clin Endocrinol Metab. 2018 Nov 1;103(11):3993-4004. doi: 10.1210/jc.2018-01225.

PMID:
30060226
22.

The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry.

Rubin MR, Zhou H, Cusano NE, Majeed R, Omeragic B, Gomez M, Nickolas TL, Dempster DW, Bilezikian JP.

J Bone Miner Res. 2018 Nov;33(11):1931-1939. doi: 10.1002/jbmr.3543. Epub 2018 Aug 16.

PMID:
29972871
23.

Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D.

Sempos CT, Heijboer AC, Bikle DD, Bollerslev J, Bouillon R, Brannon PM, DeLuca HF, Jones G, Munns CF, Bilezikian JP, Giustina A, Binkley N.

Br J Clin Pharmacol. 2018 Oct;84(10):2194-2207. doi: 10.1111/bcp.13652. Epub 2018 Jul 17. Review.

PMID:
29851137
24.

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.

Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Fitzpatrick LA, Mitlak B, Papapoulos S, Rizzoli R, Dore RK, Bilezikian JP, Saag KG.

J Clin Endocrinol Metab. 2018 Aug 1;103(8):2949-2957. doi: 10.1210/jc.2018-00163.

25.

Stop the war on DXA!

Lewiecki EM, Binkley N, Bilezikian JP.

Ann N Y Acad Sci. 2018 Dec;1433(1):12-17. doi: 10.1111/nyas.13707. Epub 2018 Apr 29.

PMID:
29707801
26.

IODINE NUTRITION IN THE REPUBLIC OF ARTSAKH (NAGORNO KARABAKH).

Hutchings N, Baghdasaryan S, Qefoyan M, Chiloyan A, Manoukian M, Atayan K, Bilezikian JP.

Endocr Pract. 2018 May;24(5):468-472. doi: 10.4158/EP-2018-0054. Epub 2018 Apr 24.

PMID:
29688765
27.

Epidemiology of hip fracture in Belarus: development of a country-specific FRAX model and its comparison to neighboring country models.

Ramanau H, Chernyanin I, Rudenka E, Lesnyak O, Zakroyeva A, Bilezikian JP, Johansson H, Harvey NC, McCloskey EV, Kanis JA.

Arch Osteoporos. 2018 Apr 17;13(1):42. doi: 10.1007/s11657-018-0454-4.

28.

Primary hyperparathyroidism: recent advances.

Walker MD, Bilezikian JP.

Curr Opin Rheumatol. 2018 Jul;30(4):427-439. doi: 10.1097/BOR.0000000000000511.

PMID:
29664757
29.

Brown tumors of primary hyperparathyroidism may be a source of extrarenal 1,25-dihydroxyvitamin D production.

Sum M, Larner D, Hewison M, Bilezikian JP.

Endocrine. 2018 Jun;60(3):524-527. doi: 10.1007/s12020-018-1579-3. Epub 2018 Mar 19. No abstract available.

PMID:
29556950
30.

Pre-operative localization of abnormal parathyroid tissue by 99mTc-sestamibi in primary hyperparathyroidism using four-quadrant site analysis: an evaluation of the predictive value of vitamin D deficiency.

Tay YD, Yeh R, Kuo JH, McManus C, Lee JA, Bilezikian JP.

Endocrine. 2018 Apr;60(1):36-45. doi: 10.1007/s12020-018-1528-1. Epub 2018 Feb 5.

PMID:
29404903
31.

Trabecular Bone Score in Obese and Nonobese Subjects With Primary Hyperparathyroidism Before and After Parathyroidectomy.

Tay YD, Cusano NE, Rubin MR, Williams J, Omeragic B, Bilezikian JP.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1512-1521. doi: 10.1210/jc.2017-02169.

PMID:
29373705
32.

New and developing pharmacotherapy for osteoporosis in men.

Gennari L, Bilezikian JP.

Expert Opin Pharmacother. 2018 Feb;19(3):253-264. doi: 10.1080/14656566.2018.1428559. Epub 2018 Jan 19. Review.

PMID:
29350069
33.

Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis.

Lewiecki EM, Bilezikian JP, Carey JJ, Dell RM, Gordon CM, Harris ST, McClung MR, Miller PD, Rosenblatt M.

J Clin Densitom. 2018 Jan - Mar;21(1):3-21. doi: 10.1016/j.jocd.2017.10.041. Epub 2017 Nov 20. Review.

PMID:
29229501
34.

Initiation of dapagliflozin and treatment-emergent fractures.

Toulis KA, Bilezikian JP, Thomas GN, Hanif W, Kotsa K, Thayakaran R, Keerthy D, Tahrani AA, Nirantharakumar K.

Diabetes Obes Metab. 2018 Apr;20(4):1070-1074. doi: 10.1111/dom.13176. Epub 2018 Jan 8.

PMID:
29193543
35.

Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.

Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D.

Osteoporos Int. 2018 Feb;29(2):323-328. doi: 10.1007/s00198-017-4304-9. Epub 2017 Nov 22.

36.

Epidemiology of fractures in Armenia: development of a country-specific FRAX model and comparison to its surrogate.

Lesnyak O, Sahakyan S, Zakroyeva A, Bilezikian JP, Hutchings N, Babalyan V, Galstyan R, Lebedev A, Johansson H, Harvey NC, McCloskey E, Kanis JA.

Arch Osteoporos. 2017 Nov 7;12(1):98. doi: 10.1007/s11657-017-0392-6.

37.

Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism.

Vokes TJ, Mannstadt M, Levine MA, Clarke BL, Lakatos P, Chen K, Piccolo R, Krasner A, Shoback DM, Bilezikian JP.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):722-731. doi: 10.1210/jc.2017-01471.

PMID:
29099947
38.

Skeletal Microstructure and Estimated Bone Strength Improve Following Parathyroidectomy in Primary Hyperparathyroidism.

Cusano NE, Rubin MR, Silva BC, Tay YD, Williams JM, Agarwal S, Omeragic B, Guo XE, Bilezikian JP.

J Clin Endocrinol Metab. 2018 Jan 1;103(1):196-205. doi: 10.1210/jc.2017-01932.

39.

Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism - translating the pharmacology.

Tay D, Cremers S, Bilezikian JP.

Br J Clin Pharmacol. 2018 Feb;84(2):252-267. doi: 10.1111/bcp.13455. Epub 2017 Dec 6. Review.

40.

Hypoparathyroidism.

Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Rejnmark L, Mitchell DM, Vokes TJ, Winer KK, Shoback DM.

Nat Rev Dis Primers. 2017 Oct 5;3:17080. doi: 10.1038/nrdp.2017.80.

PMID:
28980621
41.

Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-μg or 50-μg Daily Doses.

Bilezikian JP, Clarke BL, Mannstadt M, Rothman J, Vokes T, Lee HM, Krasner A.

Clin Ther. 2017 Oct;39(10):2096-2102. doi: 10.1016/j.clinthera.2017.08.011. Epub 2017 Sep 21.

42.

Hyperparathyroidism.

Bilezikian JP, Bandeira L, Khan A, Cusano NE.

Lancet. 2018 Jan 13;391(10116):168-178. doi: 10.1016/S0140-6736(17)31430-7. Epub 2017 Sep 17. Review.

PMID:
28923463
43.

Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism.

Misiorowski W, Czajka-Oraniec I, Kochman M, Zgliczyński W, Bilezikian JP.

Endocrine. 2017 Nov;58(2):380-385. doi: 10.1007/s12020-017-1414-2. Epub 2017 Sep 12.

44.

Hypoparathyroidism.

Mannstadt M, Bilezikian JP, Thakker RV, Hannan FM, Clarke BL, Rejnmark L, Mitchell DM, Vokes TJ, Winer KK, Shoback DM.

Nat Rev Dis Primers. 2017 Aug 31;3:17055. doi: 10.1038/nrdp.2017.55. Review. Erratum in: Nat Rev Dis Primers. 2017 Oct 05;3:17080.

PMID:
28857066
45.

Osteoporosis in Crisis: It's Time to Focus on Fracture.

Binkley N, Blank RD, Leslie WD, Lewiecki EM, Eisman JA, Bilezikian JP.

J Bone Miner Res. 2017 Jul;32(7):1391-1394. doi: 10.1002/jbmr.3182. Epub 2017 Jun 15.

46.

Proceedings of the 2016 Santa Fe Bone Symposium: New Concepts in the Management of Osteoporosis and Metabolic Bone Diseases.

Lewiecki EM, Bilezikian JP, Bukata SV, Camacho P, Clarke BL, McClung MR, Miller PD, Shepherd J.

J Clin Densitom. 2017 Apr - Jun;20(2):134-152. doi: 10.1016/j.jocd.2017.01.001. Epub 2017 Feb 6.

47.

Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate.

Fan Y, Hanai JI, Le PT, Bi R, Maridas D, DeMambro V, Figueroa CA, Kir S, Zhou X, Mannstadt M, Baron R, Bronson RT, Horowitz MC, Wu JY, Bilezikian JP, Dempster DW, Rosen CJ, Lanske B.

Cell Metab. 2017 Mar 7;25(3):661-672. doi: 10.1016/j.cmet.2017.01.001. Epub 2017 Feb 2.

48.

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.

Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D.

Mayo Clin Proc. 2017 Feb;92(2):200-210. doi: 10.1016/j.mayocp.2016.10.009.

49.

Novel Therapies for Postmenopausal Osteoporosis.

Bandeira L, Bilezikian JP.

Endocrinol Metab Clin North Am. 2017 Mar;46(1):207-219. doi: 10.1016/j.ecl.2016.11.001. Epub 2016 Dec 23. Review.

PMID:
28131134
50.

Romosozumab for the treatment of osteoporosis.

Bandeira L, Lewiecki EM, Bilezikian JP.

Expert Opin Biol Ther. 2017 Feb;17(2):255-263. doi: 10.1080/14712598.2017.1280455. Review.

PMID:
28064540

Supplemental Content

Loading ...
Support Center